Meeting
2020 ASCO Virtual Scientific Program
Ultrasensitive multiplex detection of structural rearrangements in ALK, RET, ROS1 and PD-L1 using a comprehensive next-generation sequencing assay.
Authors
Kao Chin Ngeow
Lucence Diagnostics, Singapore, Singapore
Kao Chin Ngeow , Yukti Choudhury , Kian-Hin Tan , Michelle Pek , Kim-Tien Ng , Soon Thye Lim , Jing Quan Lim , Dachuan Huang , Choon Kiat Ong , Min-Han Tan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3572)
DOI
10.1200/JCO.2020.38.15_suppl.3572
Abstract #
3572
Poster Bd #
302
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates
Poster
2021 ASCO Quality Care Symposium
Biomarker testing patterns in patients with stage IV non-small cell lung cancer (NSCLC) in U.S. community-based oncology practice setting.
First Author: Anthony Sireci
Poster
2019 ASCO Annual Meeting
Mutational landscapes and PD-L1 expression in non-small cell lung cancer.
First Author: Kang Zhang
Poster
2018 ASCO Annual Meeting
Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model.
First Author: Nathan A. Pennell